Follows adults with heart-related transthyretin amyloidosis treated with vutrisiran
Observes adults with transthyretin amyloidosis heart disease receiving vutrisiran in routine care.
Key facts
- Who runs it
- Alnylam Pharmaceuticals
- Where
- Heidelberg, Munich, Münster, and Würzburg, GermanySee the 4 sitesAlso in 2 other countries, 23 sites
- Trial code
- Registry title
- DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With ATTR-CM in a Real-World Setting
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 9 Jan 2026
- Expected to end
- 23 Oct 2030
- Type of study
- Observational
- Record updated
- 9 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) who are starting treatment with vutrisiran or another approved ATTR-CM therapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A diagnosis of ATTR-CM (transthyretin amyloidosis with cardiomyopathy)
- Earlier treatment
- People are starting treatment with vutrisiran or another approved ATTR-CM therapy.
Main reasons for not taking part
- Being enrolled in an interventional clinical trial
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Has a diagnosis of ATTR-CM
- Is initiating treatment with vutrisiran or another approved ATTR-CM therapy
Who cannot take part
- Is enrolled in an interventional clinical trial
Where in Germany
Also in 2 other countries, 23 sites
- Heidelberg, Baden-WurttembergHospital not named in the registryTaking people
- MunichHospital not named in the registryTaking people
- MünsterHospital not named in the registryTaking people
- WürzburgHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The purpose of this study is to:
Read full original descriptionShow less
* Describe the clinical characteristics of adult patients with transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM) treated with vutrisiran in routine clinical care * Describe treatment patterns of adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess health-related quality of life (HRQOL) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Assess healthcare resource use (HCRU) in adult patients with ATTR-CM treated with vutrisiran in routine clinical care * Compare the long-term effectiveness of vutrisiran versus other approved ATTR-CM treatments in routine clinical care
The group in the trial
- Patients with ATTR-CM
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- DemonsTTRate: A Global, Observational, Multicenter, Long-term Study of Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy in a Real-World Setting
- Plain-language title
- Follows adults with heart-related transthyretin amyloidosis treated with vutrisiranGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 9 October 2026